Open Nav

Antag Therapeutics ApS

Attract investment for our Series A

  • Date:Thursday, October 18
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Antag Therapeutics is developing a novel approach to treating dietary-related metabolic diseases, with obesity as our main target indication. The technology originates from the same lab where GLP-1 agonists were discovered, and we have the unique opportunity of validating our novel approach and exploring niche indications by conducting human interventional studies.
  • Company Website:
  • Company HQ City:Copenhagen
  • Company HQ Country:Denmark
  • CEO/Top Company Official:Alexander H. Sparre-Ulrich
  • Year Founded:2017
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development :AT382
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:We are advancing our lead program AT382, a once-weekly GIP antagonist expected to complete pre-clinical proof-of-concept by Q2-2019. We are seeking partnering opportunities as well as potential co-investors to participate in an eventual Series A round to fund clinical development.
  • Previous and Current Investors:Novo Holdings
  • Size of Last Investment Round:3,000,000
  • Total Amount Raised to Date, In All Rounds:3,700,000